Современные b-адреноблокаторы: диапазон свойств и обоснование предпочтений, страница 13

6. Ludden T.M., Boyle D.A., Gieseker D. et al. Absolute bioavailability and dose proportionality of betaxolol in normal healthy subjects. J Pharm Sci 1988;77(9):779-783.

7. McDevit DG, Comparison of pharmacokinetic properities of beta-adrenoreceptor blocking drugs. Europ Heart J 1987;8 Suppl M:9-14.

8. Frishman W.H., Tepper D., Lazer E.J., et al. Betaxolol: a new long-acting beta1-selective adrenergic blocker. J Clin Pharmacol 1990;30:686-692.

9. Sinclair A.J., Davies I.B., Warrington S.J. Betaxololand glucose-insulin relationships studies in normalsubjects taking glibenclamide or metformin. Br J Clin Pharmacol 1990;30(5):699-702.

10. Benn J.J., Broun P.M., Beckwith L.J. et al. Glucoose turnover in type I diabetic subjects during exesise. Diabetes Care 1992,15; Suppl 4.

11. Saku K., Zhang B., Okamoto T. et al. Medium-term effects of betaxolol monotherapy and combination therapy with nitrendipine on lipoprotein and apolipoprotein metabolism in patients with mild to moderate essential hypertension. J Human Hypertens 1996;10 (4):263-268.

12. Caccavale A., Fusco R., Romano B., et al. Effects of ocular betaxolol on glucose and lipid metabolism after long-term treatment. Clin Drug Invest 1997;14(5):363-368.

13. De Bruijn N.P., Reves J.G., Groughwell N. et al. Pharmacokinetiks of esmolol in anesthetized patients receving chronic beta blocker therapy. Anesthesiology 1987;66:323-326.

14. Sum S.Y., Yacobi A., Kartzinel R. et al. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin Pharmakol Ther 1983;34:424-434.

15. Quon C.Y., Stampfil H.F. Biochemical properties of blood esmolol esterase. Drug Metab Dispos 1985;13:420-424.

16. Yacobi A., Kartzinel R., Lai S.M. et al. Esmolol: a pharmacokinetic profile of new cardiose-lective b-blocking agent. J Pharmacol Sci 1983;72:710-711.

17. Gorczynski R.J., Shaffer J.E., Lee R.J. Pharmacology of ASL-8052, a novel b-adrenerjic receptor antagonist with an ultrashort duration of action. J Cardiovasc Pharmacol 1983;5:668-671.

18. Kaplan J.A. Role of ultrashort-acting b-blockers in the perioperative period. Cardiovasc Anesth 1988;2:683-691.

19. Sheppard D., DiStefano S., Byrd R.S. et al. Effects of esmolol on airway function in patients with asthma J Clin Pharmacol 1986;26:169-174.

20. Weber F., Schneider H., von Arnim T., Urbaszek W. Heart rate variability and ischemia in patients with coronary heart disease and stable width=100% angina pectoris; influence of drug therapy and prognostic value. TIBBS Investigators Group. Total Ischemic Burden Bisoprolol Study. Eur Heart J 1999;20(1):38-50.

21. McLenachan J.M., Findlay I.N., Wilson J.T., Dargie H.J. Twenty-four-hour beta-blockade in stable width=100% angina pectoris: a study of atenolol and betaxolol. J Cardiovasc Pharmacol 1992;20(2):311-315.

22. Alpert M.A., Mukerji V., Villarreal D. et al. Efficacy of betaxolol in the treatment of stable width=100% exertional angina pectoris: a dose-ranging study. Angiology 1990;41(5):365-376

23. Alpert M.A., Singh A., Holmes R.A. et al. Effect of beta blockade with betaxolol on left ventricular systolic function in chronic stable width=100% angina pectoris and left ventricular dysfunction. Am J Cardiol 1986:1;57(10):721-724.

24. Gibbons R.J., Chatterjee K., Daley J., et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable width=100% angina: executive summary and recommendations: a report of the American College of Cardiology/AmericanHeart Association task force on practice Guidelines (Commitee on Management of Patients with Chronic Stable width=100% angina). Circulation 1999;99(21):2829-2848.

25. Yusuf S., Peto R., Lewis J. et al. Beta blocade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27(5):335-371

26. Hjalmarson A. cardiprotection with beta-adrenoreceptor blockers. Does lipophilicity matter? Basic Res Cardiol 2000;95 Suppl 1:I41-I45.

27. Kjekshus J.K. Importance of heart rate in determining b-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986;57:43F-49F.